Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 56, 2021 - Issue 10
Submit an article Journal homepage
2,886
Views
6
CrossRef citations to date
0
Altmetric
Original Article

First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study

Karoline Anisdahla Department of Gastroenterology, Oslo University Hospital, Oslo, Norway;b Institute of Clinical Medicine, University of Oslo, Oslo, NorwayCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2041-9100View further author information
ORCID Icon,
Sandre Svatun Lirhusc Department of Health Management and Health Economics, University of Oslo, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0002-0895-7654View further author information
ORCID Icon,
Asle W. Medhusa Department of Gastroenterology, Oslo University Hospital, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0001-7118-5127View further author information
ORCID Icon,
Bjørn Mouma Department of Gastroenterology, Oslo University Hospital, Oslo, Norway;b Institute of Clinical Medicine, University of Oslo, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0002-5884-4543View further author information
ORCID Icon,
Hans Olav Melbergc Department of Health Management and Health Economics, University of Oslo, Oslo, NorwayView further author information
&
Marte Lie Høivika Department of Gastroenterology, Oslo University Hospital, Oslo, Norway;b Institute of Clinical Medicine, University of Oslo, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0002-0104-465XView further author information
ORCID Icon
Pages 1163-1168 | Received 18 May 2021, Accepted 07 Jul 2021, Published online: 28 Jul 2021

References

  • Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340(18):1398–1405.
  • Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876–885.
  • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
  • Péntek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn's disease in ten European countries. World Journal of Gastroenterology. 2017;23(34):6294–6305.
  • Lirhus SS, Hoivik ML, Moum B, et al. Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study. Scand J Gastroenterol. 2018;53(8):952–957.
  • Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
  • Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
  • D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371(9613):660–667.
  • Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201.
  • Marchetti M, Liberato NL, Di Sabatino A, et al. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ. 2013;14(6):853–861.
  • Baji P, Gulácsi L, Brodszky V, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. United European Gastroenterol J. 2018;6(2):310–321.
  • Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in european off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34:159–170.
  • Lirhus SS, Høivik ML, Moum B, et al. Incidence and prevalence of inflammatory bowel disease in Norway and the impact of different case definitions: a nationwide registry study. Clin Epidemiol. 2021;13:287–294.
  • Sykehusinnkjøp HF. Pharmaceutical strategy of the Norwegian hospital procurement trust. 2020. [updated 2020 Feb 19 02; cited 2020 Jul 10]. Available from: https://sykehusinnkjop.no/pharmaceutical-strategy-of-the-norwegian-hospital-procurement-trust-sykehusinnkjop-hf-
  • Alulis S, Vadstrup K, Borsi A, et al. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015. Scand J Gastroenterol. 2020;55(3):265–271.
  • Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20(1):36–46.
  • Patil SA, Rustgi A, Langenberg P, et al. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci. 2013;58(1):209–215.
  • Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PloS One. 2020;15(1):e0227914.
  • Panaccione R, Colombel J-F, Travis S, et al. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut. 2020;69(4):658–664.
  • Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
  • Buer LC, Moum BA, Cvancarova M, et al. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017;11(3):297–304.
  • Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a belgian case study. Pharmacoeconomics. 2014;32(7):681–691.
  • Jakobsson GL, Sternegård E, Olén O, et al. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand J Gastroenterol. 2017;52(2):216–221.
  • Lo B, Vind I, Vester-Andersen MK, et al. Validation of ulcerative colitis and Crohn's disease and their phenotypes in the Danish National Patient Registry using a population-based cohort. Scand J Gastroenterol. 2020;55(10):1171–1175.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.